<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806779</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00042699</org_study_id>
    <secondary_id>1P50DA027840-01A1</secondary_id>
    <nct_id>NCT01806779</nct_id>
  </id_info>
  <brief_title>Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers</brief_title>
  <acronym>ConNic5</acronym>
  <official_title>Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philip Morris USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous results from the investigators' Center have shown that combination treatment with
      Chantix and Zyban is more successful in helping men quit smoking. The investigators hope to
      replicate these findings with this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Completing Continuous Four-week Abstinence From Smoking Between the 8-week and 11-week Post Quit Day Visits</measure>
    <time_frame>Period between 8-week and 11-week visits post target Quit Day</time_frame>
    <description>This will be determined by a composite of self-report at the 11-week study visit of no smoking between the 8-week and 11-week visits and expired air carbon monoxide (CO) &lt;10 ppm (measured at the 11-week study visit). An intent-to-treat criterion will be used, whereby drop-outs are considered to be non-abstinent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Completing Seven-day Point Abstinence From Smoking at 6 Months Post Quit Day</measure>
    <time_frame>6 months post Quit Day</time_frame>
    <description>This will be determined by a self-report of no smoking for the previous seven days when called for 6-month follow-up confirmed by expired air CO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Completing Continuous Abstinence From Smoking Between Quit Day and 11-week Post Quit Day Visit</measure>
    <time_frame>Quit Day to 11-week post Quit Day study visit</time_frame>
    <description>This will be determined by a composite of self-report of no smoking between study visits at the 1-week, 3-week, 7-week and 11-week post Quit Day study visits and expired air carbon monoxide (CO) &lt;10 ppm (measured at those study visits). An intent-to-treat criterion will be used, whereby drop-outs are considered to be non-abstinent.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Smoking Withdrawal Symptoms</measure>
    <time_frame>Quit Day and 1 week, 3 weeks, 7 Weeks, 11 Weeks and 6 months post Quit Day</time_frame>
    <description>Withdrawal symptoms will be assessed by questionnaire on Quit Day, Week 1, Week 3, Week 7 and Week 11 post target quit date and 6 months post quit Follow-Up (if applicable) using the Shiffman-Jarvik questionnaire, which consists of 33-items rated from 1 to 7, where 1= not at all, 2= very little, 3= a little, 4= moderately, 5= a lot, 6= quite a lot, and 7= extremely. The 33 items are grouped into 8 subscales: Craving, Negative Affect, Appetite, Arousal, Somatic - Anxiety, Somatic - G.I., Somatic - Respiratory Tract, and Habit Withdrawal. The range of scores for each subscale will be 1-7, with higher scores indicating more of the withdrawal symptom having been experienced.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">376</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Chantix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the first 3 days after being switched from Nicotine Replacement Therapy (NRT) (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chantix + Zyban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For the first 3 days after being switched from NRT (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chantix</intervention_name>
    <arm_group_label>Chantix</arm_group_label>
    <arm_group_label>Chantix + Zyban</arm_group_label>
    <other_name>Varenicline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zyban</intervention_name>
    <arm_group_label>Chantix + Zyban</arm_group_label>
    <other_name>Bupropion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine patches</intervention_name>
    <description>All participants will receive 21 mg/24 h dose nicotine (nic.) patches for 1 week.</description>
    <arm_group_label>Chantix</arm_group_label>
    <arm_group_label>Chantix + Zyban</arm_group_label>
    <other_name>NRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have no known serious medical conditions;

          -  Male;

          -  Are 18-65 years old;

          -  Smoke an average of at least 10 cigarettes per day;

          -  Have smoked at least one cumulative year;

          -  Have an expired air carbon monoxide (CO) reading of at least 10ppm;

          -  Able to read and understand English;

          -  Express a desire to quit smoking in the next thirty days.

        Potential subjects must agree to use acceptable contraception.

        Potential subjects must agree to avoid the following:

          -  participation in any other nicotine-related modification strategy outside of this
             protocol;

          -  use of tobacco products other than cigarettes, including pipe tobacco, cigars,
             e-cigarettes, snuff, and chewing tobacco;

          -  use of experimental (investigational) drugs or devices;

          -  use of illegal drugs;

          -  use of opiate medications.

        Exclusion Criteria:

          -  Hypertension;

          -  Hypotension with symptoms;

          -  Coronary heart disease;

          -  Lifetime history of heart attack;

          -  Cardiac rhythm disorder (irregular heart rhythm);

          -  Chest pains (unless history, exam, and electrocardiogram (ECG) clearly indicate a
             non-cardiac source);

          -  Cardiac (heart) disorder (including but not limited to valvular heart disease, heart
             murmur, heart failure);

          -  History of skin allergy;

          -  Active skin disorder (e.g., psoriasis) within the last five years;

          -  Liver or kidney disorder (except kidney stones, gallstones);

          -  Gastrointestinal problems or disease other than gastroesophageal reflux or heartburn;

          -  Active ulcers in the past 30 days;

          -  Currently symptomatic lung disorder/disease (including but not limited to Chronic
             obstructive pulmonary disease (COPD), emphysema, and asthma);

          -  Brain abnormality (including but not limited to stroke, brain tumor, and seizure
             disorder);

          -  Migraine headaches that occur more frequently than once per week;

          -  Recent, unexplained fainting spells;

          -  Problems giving blood samples;

          -  Diabetes treated with insulin; non-insulin treated diabetes (unless glucose is less
             than 180mg/dcl and HbA1c is less than 7%);

          -  Current cancer or treatment for cancer in the past six months (except basal or
             squamous cell skin cancer);

          -  Other major medical condition;

          -  Current psychiatric disease (with the exception of anxiety disorders, Obsessive
             Compulsive Disorder (OCD) and ADHD);

          -  Suicidal ideation (within the past 10 years) or lifetime occurrence of attempted
             suicide;

          -  Current depression;

          -  Bulimia or anorexia;

          -  Use of opiate medications for pain or sleep (non-opiate medication for pain or sleep
             will be allowed) within the past 14 days;

          -  Smoking more than one cigar a month.

          -  Alcohol abuse;

          -  Significant adverse reaction to nicotine patches, bupropion / Wellbutrin / Zyban or
             Chantix / varenicline in the past.

          -  Current participation or recent participation (in the past 30 days) in another smoking
             study at our Center or another research facility.

          -  Current participation in another research study.

        Use (within the past 30 days) of:

          -  Illegal drugs (or if the urine drug screen is positive for tetrahydrocannabinol (THC),
             Cocaine, Amphetamine, Opiates, Methamphetamines, phencyclidine (PCP), Benzodiazepines,
             or Barbiturates),

          -  Experimental (investigational) drugs;

          -  Psychiatric medications including antidepressants, anti-psychotics or any other
             medications that are known to affect smoking cessation (e.g. clonidine);

          -  Smokeless tobacco (chewing tobacco, snuff), pipes or e-cigarettes;

          -  Wellbutrin, bupropion, Zyban, Chantix, varenicline, nicotine replacement therapy or
             any other smoking cessation aid.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jed E Rose, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Center for Smoking Cessation</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Center for Smoking Cessation</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Center for Smoking Cessation</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Center for Smoking Cessation</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2013</study_first_posted>
  <results_first_submitted>September 3, 2015</results_first_submitted>
  <results_first_submitted_qc>September 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 8, 2015</results_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nicotine addiction</keyword>
  <keyword>Cigarette smoking</keyword>
  <keyword>Smoking cessation</keyword>
  <keyword>Zyban</keyword>
  <keyword>Chantix</keyword>
  <keyword>Nicotine patches</keyword>
  <keyword>varenicline</keyword>
  <keyword>bupropion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Varenicline</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began on 3/4/2013 and ended on 9/7/2014. Of the 376 subjects (subjs.) consented during this period, 197 subjects met all study criteria.</recruitment_details>
      <pre_assignment_details>Of the 376 subjs. enrolled, 179 were withdrawn by study staff or withdrew voluntarily from further participation prior to the 1st study visit (V1). 197 subjs. met all study criteria, attended V1 &amp; given NRT for 1 week; 176 subjs. attended V2 &amp; completed SE quest.; 2 subjs. dropped out during this visit before randomization; 174 subjs. randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Chantix</title>
          <description>For the first 3 days after being switched from Nicotine Replacement Therapy (NRT, occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
Chantix
Nicotine patches: All participants will receive 21 mg/24 h dose nicotine patches for 1 week.</description>
        </group>
        <group group_id="P2">
          <title>Chantix + Zyban</title>
          <description>For the first 3 days after being switched from NRT (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.
Chantix
Zyban
Nicotine patches: All participants will receive 21 mg/24 h dose nicotine patches for 1 week.</description>
        </group>
        <group group_id="P3">
          <title>Nicotine Patches Only</title>
          <description>These subjects received nicotine patches at the first study visit but dropped out before randomization. 176 subjects attended the second study visit and provided side effects (SE) data. Two of these subjects dropped out during that visit (after providing SE data but prior to randomization). So, out of the initial 197 subjects receiving nicotine patches, 174 went on to receive Chantix or Chantix+Zyban; 23 subjects only received nicotine patches before dropping out.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="23">All 197 subjects received nicotine patches but 23 dropped before receiving other study drugs.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed SE Quest. After Using Patches</title>
              <participants_list>
                <participants group_id="P1" count="90">SE quest. = Side Effects Questionnaire</participants>
                <participants group_id="P2" count="84">SE quest. = Side Effects Questionnaire</participants>
                <participants group_id="P3" count="2">SE quest. = Side Effects Questionnaire</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized at Visit 2</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed SE Quest. After Randomization</title>
              <participants_list>
                <participants group_id="P1" count="87">SE quest. = Side Effects Questionnaire</participants>
                <participants group_id="P2" count="83">SE quest. = Side Effects Questionnaire</participants>
                <participants group_id="P3" count="0">SE quest. = Side Effects Questionnaire</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chantix</title>
          <description>For the first 3 days after being switched from Nicotine Replacement Therapy (NRT, occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
Chantix
Nicotine patches: All participants will receive 21 mg/24 h dose nicotine patches for 1 week.</description>
        </group>
        <group group_id="B2">
          <title>Chantix + Zyban</title>
          <description>For the first 3 days after being switched from NRT (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.
Chantix
Zyban
Nicotine patches: All participants will receive 21 mg/24 h dose nicotine patches for 1 week.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="84"/>
            <count group_id="B3" value="174"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.75" spread="11.381"/>
                    <measurement group_id="B2" value="43.12" spread="10.562"/>
                    <measurement group_id="B3" value="43.96" spread="10.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Completing Continuous Four-week Abstinence From Smoking Between the 8-week and 11-week Post Quit Day Visits</title>
        <description>This will be determined by a composite of self-report at the 11-week study visit of no smoking between the 8-week and 11-week visits and expired air carbon monoxide (CO) &lt;10 ppm (measured at the 11-week study visit). An intent-to-treat criterion will be used, whereby drop-outs are considered to be non-abstinent.</description>
        <time_frame>Period between 8-week and 11-week visits post target Quit Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chantix</title>
            <description>For the first 3 days after being switched from Nicotine Replacement Therapy (NRT, occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
Chantix
Nicotine patches: All participants will receive 21 mg/24 h dose nicotine patches for 1 week.</description>
          </group>
          <group group_id="O2">
            <title>Chantix + Zyban</title>
            <description>For the first 3 days after being switched from NRT (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.
Chantix
Zyban
Nicotine patches: All participants will receive 21 mg/24 h dose nicotine patches for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Completing Continuous Four-week Abstinence From Smoking Between the 8-week and 11-week Post Quit Day Visits</title>
          <description>This will be determined by a composite of self-report at the 11-week study visit of no smoking between the 8-week and 11-week visits and expired air carbon monoxide (CO) &lt;10 ppm (measured at the 11-week study visit). An intent-to-treat criterion will be used, whereby drop-outs are considered to be non-abstinent.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Completing Seven-day Point Abstinence From Smoking at 6 Months Post Quit Day</title>
        <description>This will be determined by a self-report of no smoking for the previous seven days when called for 6-month follow-up confirmed by expired air CO.</description>
        <time_frame>6 months post Quit Day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chantix</title>
            <description>For the first 3 days after being switched from Nicotine Replacement Therapy (NRT, occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
Chantix
Nicotine patches: All participants will receive 21 mg/24 h dose nicotine patches for 1 week.</description>
          </group>
          <group group_id="O2">
            <title>Chantix + Zyban</title>
            <description>For the first 3 days after being switched from NRT (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.
Chantix
Zyban
Nicotine patches: All participants will receive 21 mg/24 h dose nicotine patches for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Completing Seven-day Point Abstinence From Smoking at 6 Months Post Quit Day</title>
          <description>This will be determined by a self-report of no smoking for the previous seven days when called for 6-month follow-up confirmed by expired air CO.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Completing Continuous Abstinence From Smoking Between Quit Day and 11-week Post Quit Day Visit</title>
        <description>This will be determined by a composite of self-report of no smoking between study visits at the 1-week, 3-week, 7-week and 11-week post Quit Day study visits and expired air carbon monoxide (CO) &lt;10 ppm (measured at those study visits). An intent-to-treat criterion will be used, whereby drop-outs are considered to be non-abstinent.</description>
        <time_frame>Quit Day to 11-week post Quit Day study visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chantix</title>
            <description>For the first 3 days after being switched from Nicotine Replacement Therapy (NRT, occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
Chantix
Nicotine patches: All participants will receive 21 mg/24 h dose nicotine patches for 1 week.</description>
          </group>
          <group group_id="O2">
            <title>Chantix + Zyban</title>
            <description>For the first 3 days after being switched from NRT (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.
Chantix
Zyban
Nicotine patches: All participants will receive 21 mg/24 h dose nicotine patches for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Completing Continuous Abstinence From Smoking Between Quit Day and 11-week Post Quit Day Visit</title>
          <description>This will be determined by a composite of self-report of no smoking between study visits at the 1-week, 3-week, 7-week and 11-week post Quit Day study visits and expired air carbon monoxide (CO) &lt;10 ppm (measured at those study visits). An intent-to-treat criterion will be used, whereby drop-outs are considered to be non-abstinent.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Smoking Withdrawal Symptoms</title>
        <description>Withdrawal symptoms will be assessed by questionnaire on Quit Day, Week 1, Week 3, Week 7 and Week 11 post target quit date and 6 months post quit Follow-Up (if applicable) using the Shiffman-Jarvik questionnaire, which consists of 33-items rated from 1 to 7, where 1= not at all, 2= very little, 3= a little, 4= moderately, 5= a lot, 6= quite a lot, and 7= extremely. The 33 items are grouped into 8 subscales: Craving, Negative Affect, Appetite, Arousal, Somatic - Anxiety, Somatic - G.I., Somatic - Respiratory Tract, and Habit Withdrawal. The range of scores for each subscale will be 1-7, with higher scores indicating more of the withdrawal symptom having been experienced.</description>
        <time_frame>Quit Day and 1 week, 3 weeks, 7 Weeks, 11 Weeks and 6 months post Quit Day</time_frame>
        <population>A total of 163 subjects (Chantix n=82, Chantix+Zyban n=81) attended the first post-quit visit. However, ten subjects (5 in each condition) failed to complete or return their Quit Day withdrawal questionnaires; therefore change scores could only be calculated for 153 subjects (Chantix n=77, Chantix+Zyban n=76).</population>
        <group_list>
          <group group_id="O1">
            <title>Chantix</title>
            <description>For the first 3 days after being switched from Nicotine Replacement Therapy (NRT, occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
Chantix
Nicotine patches: All participants will receive 21 mg/24 h dose nicotine patches for 1 week.</description>
          </group>
          <group group_id="O2">
            <title>Chantix + Zyban</title>
            <description>For the first 3 days after being switched from NRT (occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.
Chantix
Zyban
Nicotine patches: All participants will receive 21 mg/24 h dose nicotine patches for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Smoking Withdrawal Symptoms</title>
          <description>Withdrawal symptoms will be assessed by questionnaire on Quit Day, Week 1, Week 3, Week 7 and Week 11 post target quit date and 6 months post quit Follow-Up (if applicable) using the Shiffman-Jarvik questionnaire, which consists of 33-items rated from 1 to 7, where 1= not at all, 2= very little, 3= a little, 4= moderately, 5= a lot, 6= quite a lot, and 7= extremely. The 33 items are grouped into 8 subscales: Craving, Negative Affect, Appetite, Arousal, Somatic - Anxiety, Somatic - G.I., Somatic - Respiratory Tract, and Habit Withdrawal. The range of scores for each subscale will be 1-7, with higher scores indicating more of the withdrawal symptom having been experienced.</description>
          <population>A total of 163 subjects (Chantix n=82, Chantix+Zyban n=81) attended the first post-quit visit. However, ten subjects (5 in each condition) failed to complete or return their Quit Day withdrawal questionnaires; therefore change scores could only be calculated for 153 subjects (Chantix n=77, Chantix+Zyban n=76).</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Craving -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.15" spread="2.354"/>
                    <measurement group_id="O2" value="-15.49" spread="3.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.06" spread="3.520"/>
                    <measurement group_id="O2" value="-28.64" spread="4.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving -- % change 7 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.94" spread="3.124"/>
                    <measurement group_id="O2" value="-28.75" spread="5.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving -- % change 11 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.97" spread="4.471"/>
                    <measurement group_id="O2" value="-30.82" spread="5.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craving -- % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.96" spread="6.563"/>
                    <measurement group_id="O2" value="-33.52" spread="9.020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.45" spread="2.551"/>
                    <measurement group_id="O2" value="-7.15" spread="2.791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.74" spread="2.494"/>
                    <measurement group_id="O2" value="-4.72" spread="4.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect -- % change 7 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.16" spread="2.885"/>
                    <measurement group_id="O2" value="-10.88" spread="4.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect -- % change 11 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.06" spread="3.396"/>
                    <measurement group_id="O2" value="-8.52" spread="4.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Affect -- % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.55" spread="10.707"/>
                    <measurement group_id="O2" value="21.96" spread="19.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.53" spread="3.148"/>
                    <measurement group_id="O2" value="-4.40" spread="3.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.04" spread="5.065"/>
                    <measurement group_id="O2" value="-4.42" spread="5.553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite -- % change 7 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.30" spread="5.981"/>
                    <measurement group_id="O2" value="-11.66" spread="6.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite -- % change 11 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.20" spread="7.153"/>
                    <measurement group_id="O2" value="-8.64" spread="8.199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite -- % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.88" spread="10.872"/>
                    <measurement group_id="O2" value="-35.44" spread="15.819"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.03" spread="5.620"/>
                    <measurement group_id="O2" value="10.72" spread="3.716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.87" spread="5.675"/>
                    <measurement group_id="O2" value="-4.40" spread="3.643"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal -- % change 7 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" spread="6.763"/>
                    <measurement group_id="O2" value="-4.03" spread="3.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal -- % change 11 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.33" spread="6.117"/>
                    <measurement group_id="O2" value="-1.56" spread="3.928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arousal -- % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.80" spread="15.516"/>
                    <measurement group_id="O2" value="49.01" spread="32.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.22" spread="3.480"/>
                    <measurement group_id="O2" value="-12.26" spread="2.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.66" spread="4.001"/>
                    <measurement group_id="O2" value="-14.40" spread="3.517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety -- % change 7 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.82" spread="3.25"/>
                    <measurement group_id="O2" value="-12.50" spread="5.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety -- % change 11 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.34" spread="3.526"/>
                    <measurement group_id="O2" value="-19.83" spread="3.768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety -- % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.77" spread="3.269"/>
                    <measurement group_id="O2" value="-57.15" spread="6.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="3.720"/>
                    <measurement group_id="O2" value="-7.78" spread="2.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.14" spread="2.994"/>
                    <measurement group_id="O2" value="-10.07" spread="2.791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal -- % change 7 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.67" spread="3.231"/>
                    <measurement group_id="O2" value="-8.44" spread="4.777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal - % change 11 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.05" spread="3.357"/>
                    <measurement group_id="O2" value="-9.60" spread="3.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal - % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.72" spread="3.245"/>
                    <measurement group_id="O2" value="-56.61" spread="6.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="3.113"/>
                    <measurement group_id="O2" value="-7.47" spread="2.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" spread="4.694"/>
                    <measurement group_id="O2" value="-8.81" spread="3.697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory -- % change 7 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="6.534"/>
                    <measurement group_id="O2" value="-18.04" spread="4.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory -- % change 11 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.36" spread="6.014"/>
                    <measurement group_id="O2" value="-19.67" spread="4.507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory -- % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.87" spread="3.293"/>
                    <measurement group_id="O2" value="-55.77" spread="6.618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Habit -- % change 1 week from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.15" spread="4.878"/>
                    <measurement group_id="O2" value="1.64" spread="5.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Habit -- % change 3 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.67" spread="4.959"/>
                    <measurement group_id="O2" value="-16.07" spread="3.735"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Habit -- % change 7 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.46" spread="6.666"/>
                    <measurement group_id="O2" value="-20.55" spread="4.868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Habit -- % change 11 weeks from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.61" spread="6.601"/>
                    <measurement group_id="O2" value="-24.78" spread="6.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Habit -- % change 6 months from Quit Day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.97" spread="4.807"/>
                    <measurement group_id="O2" value="-53.40" spread="5.905"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects (subjs.) received (rcvd.) study drugs for 13 weeks. At each study session during this period subjs. completed a questionnaire about side effects (SE). Subjs. were also told to contact study staff between study sessions if SE were bothersome.</time_frame>
      <desc>Serious Adverse Events (AE) were evaluated for all subjs. who rcvd. nic. patches at Visit (V) 1 (197), &amp; subjs. randomized to receive Chantix (90) or Chantix+Zyban (84) at V2. Other AEs were evaluated for all subjs. receiving nic. patches &amp; completing V2 SE quest. (176), &amp; randomized subjs. completing SE quest. at V3 (170) &amp; at subsequent visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>Chantix</title>
          <description>For the first 3 days after being switched from Nicotine Replacement Therapy (NRT, occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
Chantix
Nicotine patches: All participants will receive 21 mg/24 h dose nicotine patches for 1 week.</description>
        </group>
        <group group_id="E2">
          <title>Chantix + Zyban</title>
          <description>For the first 3 days after being switched from Nicotine Replacement Therapy (NRT, occurring at one week after initiation of nicotine patch treatment, one week before the target Quit Day), smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week plus Zyban at a dose of 150mg once per day. Subsequently, the dose of Chantix will be 1 mg twice per day and the dose of Zyban will be 150 mg twice per day for the remainder of the 12-week active treatment duration.
Chantix
Zyban
Nicotine patches: All participants will receive 21 mg/24 h dose nicotine patches for 1 week.</description>
        </group>
        <group group_id="E3">
          <title>Nicotine Patch</title>
          <description>All participants will receive Nicotine Replacement Therapy (NRT) in the form of 21 mg/24 h dose nicotine patches for 1 week prior to randomization to treatment with Chantix alone or Chantix + Zyban.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac Chest Pain &amp; Right Ventricular Hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Left sided weakness, headache, blurred vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Jaw &amp; upper extremity fracture due to an accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD and reactive airway disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction to Chantix or Zyban</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="83"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E2" events="19" subjects_affected="11" subjects_at_risk="83"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E2" events="32" subjects_affected="15" subjects_at_risk="83"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Decreased Libido</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint/Muscle/Back Pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E2" events="12" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Excessive Sweating</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Change in Taste</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E2" events="26" subjects_affected="17" subjects_at_risk="83"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="83"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Vivid Dreams</sub_title>
                <counts group_id="E1" events="29" subjects_affected="13" subjects_at_risk="87"/>
                <counts group_id="E2" events="38" subjects_affected="19" subjects_at_risk="83"/>
                <counts group_id="E3" events="30" subjects_affected="30" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E2" events="17" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching/Burning at Patch Site</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jed E. Rose</name_or_title>
      <organization>Duke Center for Smoking Cessation</organization>
      <phone>919-668-5055</phone>
      <email>jed.rose@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

